XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Agreements (Details) - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
May 06, 2016
Dec. 29, 2015
Sep. 25, 2017
Jul. 24, 2017
May 26, 2017
Feb. 28, 2017
Mar. 31, 2016
Sep. 30, 2018
Dec. 31, 2017
Sep. 30, 2017
Collaborative Agreements (Textual)                    
Outstanding balance               $ 2,550,000 $ 2,550,000  
Collaborative Arrangement [Member]                    
Collaborative Agreements (Textual)                    
Description of payment settlement   <table cellspacing="0" cellpadding="0" style="font: 12pt times new roman, times, serif; width: 100%; border-collapse: collapse"><tr><td style="vertical-align: bottom; width: 48px"> </td><td style="vertical-align: top; width: 24px"><font style="font-size: 10pt">●</font></td><td style="text-align: justify"><font style="font-size: 10pt">upfront payment shall upon the signing of this BioLite Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week.</font></td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"><font style="font-size: 10pt">●</font></td><td style="text-align: justify"><font style="font-size: 10pt">upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</font></td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr></table><p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr><td style="vertical-align: bottom; width: 48px"> </td><td style="vertical-align: top; width: 24px"><font style="font-size: 10pt">●</font></td><td style="text-align: justify"><font style="font-size: 10pt">at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months.</font></td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"><font style="font-size: 10pt">●</font></td><td style="text-align: justify"><font style="font-size: 10pt">upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week.</font></td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"><font style="font-size: 10pt">●</font></td><td style="text-align: justify"><font style="font-size: 10pt">at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months.</font></td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"> </td><td style="text-align: justify"> </td></tr><tr><td style="vertical-align: bottom"> </td><td style="vertical-align: top"><font style="font-size: 10pt">●</font></td><td style="vertical-align: bottom"><font style="font-size: 10pt">upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. </font></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>                
Amount received from BriVision   $ 100,000,000   $ 3,000,000            
Upfront payments   $ 3,500,000                
Percentage of payments under collaborative agreement   3.50%   50.00%       15.00%    
Milestone payments to BioLite in cash $ 2,600,000                  
Common stock newly issued, value $ 900,000     $ 3,000,000            
Common stock newly issued, shares 562,500                  
Share price $ 1.60         $ 2.0        
Licensing rights               $ 10,000,000    
Accounts payable               $ 15,000,000    
Agreement, terms   This BioLite Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.                
Collaborative Arrangement One [Member]                    
Collaborative Agreements (Textual)                    
Percentage of payments under collaborative agreement             6.50%      
Milestone payments to BioLite in cash           $ 650,000        
Common stock newly issued, value           $ 5,850,000        
Common stock newly issued, shares           2,925,000        
Share price           $ 2.00        
Licensing rights     $ 3,000,000              
Accounts payable             $ 6,500,000      
Research and development expense                 3,000,000  
Co-Dev Agreement [Member]                    
Collaborative Agreements (Textual)                    
Amount received from BriVision         $ 3,000,000         $ 450,000
Percentage of payments under collaborative agreement         50.00%          
Company cash payments         $ 3,000,000       $ 3,000,000  
Outstanding balance                   $ 2,550,000